Review of pharmacological therapies in fibromyalgia syndrome

Winfried Häuser, Brian Walitt, Mary-Ann Fitzcharles, Claudia Sommer, Winfried Häuser, Brian Walitt, Mary-Ann Fitzcharles, Claudia Sommer

Abstract

This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration.

References

    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russel IJ, Sheon RP. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;16:160–172. doi: 10.1002/art.1780330203.
    1. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;16:448–453. doi: 10.1016/j.semarthrit.2008.12.003.
    1. Ablin JN, Oren A, Cohen S, Aloush V, Buskila D, Elkayam O, Wollman Y, Berman M. Prevalence of fibromyalgia in the Israeli population: a population-based study to estimate the prevalence of fibromyalgia in the Israeli population using the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) Clin Exp Rheumatol. 2012;16:39–43.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;16:1113–1122. doi: 10.3899/jrheum.100594.
    1. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken) 2013;16:777–785. doi: 10.1002/acr.21931.
    1. Häuser W, Zimmer C, Felde E, Köllner V. What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz. 2008;16:176–183. doi: 10.1007/s00482-007-0602-z. In German.
    1. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm. 2012;16:415–426.
    1. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;16:1560–1570. doi: 10.1002/art.1780400904.
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;16:27. doi: 10.1186/1471-2474-8-27.
    1. Häuser W, Jung E, Erbslöh-Möller B, Gesmann M, Kühn-Becker H, Petermann F, Langhorst J, Thoma R, Weiss T, Wolfe F, Winkelmann A. German fibromyalgia consumer reports - a crosssectional survey. BMC Musculoskelet Disord. 2012;16:74. doi: 10.1186/1471-2474-13-74.
    1. Wilson AL. Influencing prescribers. Top Hosp Pharm Manage. 1994;16:40–46.
    1. Frost & Sullivan Healthcare and Life Sciences Consulting Group. Assessment of the U.S. Fibromyalgia Market in Support of S1 Filing (Phase 2) [ ]
    1. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, Ko G, Moulin DE, Panopalis P, Proulx J, Shir Y. National Fibromyalgia Guideline Advisory Panel. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: Executive Summary. Pain Res Manag. 2013;16:119–126.
    1. Eich W, Häuser W, Arnold B, Bernardy K, Brückle W, Eidmann U, Klimczyk K, Köllner V, Kühn-Becker H, Offenbächer M, Settan M, von Wachter M, Petzke F. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz. 2012;16:268–275. doi: 10.1007/s00482-012-1167-z.
    1. Häuser W, Bernardy K, Wang H, Kopp I. Methodological fundamentals of the development of the guideline. Schmerz. 2012;16:232–246. doi: 10.1007/s00482-012-1189-6. In German.
    1. Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz. 2012;16:297–310. doi: 10.1007/s00482-012-1172-2.
    1. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013;16:CD010292.
    1. Tort S, Urrútia G, Nishishinya MB, Walitt B. Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2012;16:CD009807.
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;16:CD008242.
    1. Häuser W, Wolfe F, Tölle T, Üçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;16:297–307. doi: 10.2165/11598970-000000000-00000.
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;16:CD007076.
    1. Üçeyler N, Sommer C, Waliit B, Häuser W. Anticonvulsants in fibromyalgia syndrome. Cochrane Database Syst Rev. 2013;16:CD010782.
    1. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol. 2005;16:49–52. doi: 10.1097/00004850-200501000-00010.
    1. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;16:581–586. doi: 10.1002/j.1532-2149.2012.00234.x.
    1. Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R. Real-world role of tricyclic antidepressants in the treatment of fibromyalgia. Pain Pract. 2012;16:533–540. doi: 10.1111/j.1533-2500.2011.00526.x.
    1. Canadian Agency for Drugs and Technology in Health. Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence. 24 April 2012. [ ]
    1. Häuser W, Bartram-Wunn E, Bartram C, Reinecke H, Tölle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain. 2011;16:1709–1717. doi: 10.1016/j.pain.2011.01.050.
    1. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol. 2012;16:78–87.
    1. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;16:519–527. doi: 10.1002/art.21319.
    1. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;16:250–257. doi: 10.1097/00124743-200010000-00003.
    1. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;16:9–13. doi: 10.1002/art.20076.
    1. Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;16:2653–2663. doi: 10.3899/jrheum.110194.
    1. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;16:2495–2505. doi: 10.1002/art.21191.
    1. Painter JT, Crofford LJ, Talbert J. Geographic variation of chronic opioid use in fibromyalgia. Clin Ther. 2013;16:303–311. doi: 10.1016/j.clinthera.2013.02.003.
    1. Marschall U, Arnold B, Häuser W. Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008–2009. Schmerz. 2011;16:402–404. doi: 10.1007/s00482-011-1079-3. 406–410. In German.
    1. Callejas Rubio JL, Fernández Moyano A, Navarro Hidalgo D, Palmero Palmero C. [Percutaneous fentanyl in fibromyalgia] Med Clin (Barc) 2003;16:358–359. doi: 10.1016/S0025-7753(03)73702-6. In Spanish.
    1. Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y. Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat. 2013;16:898493.
    1. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol. 2013;16:72–77. doi: 10.1097/RHU.0b013e3182863447.
    1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;16:113–130. doi: 10.1016/j.jpain.2008.10.008.
    1. Ramiro S, Radner H, van der Heijde DM, Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012;16:47–55. doi: 10.3899/jrheum.120342.
    1. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;16:164–173. doi: 10.1016/j.jpain.2007.09.002.
    1. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;16:604–610. doi: 10.1213/ANE.0b013e3181c76f70.
    1. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;16:494–503. doi: 10.1111/j.1360-0443.2009.02776.x.
    1. Cuatrecasas G, Alegre C, Fernandez-Solà J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, Lage M, Peinó R, Casanueva F, Liñan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain. 2012;16:1382–1389. doi: 10.1016/j.pain.2012.02.012.
    1. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998;16:227–231. doi: 10.1016/S0002-9343(97)00351-3.
    1. Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab. 2010;16:4331–4337. doi: 10.1210/jc.2010-0061.
    1. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs. 2012;16:135–153. doi: 10.2165/11597130-000000000-00000.
    1. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2012;16:1–14.
    1. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;16:529–538. doi: 10.1002/art.37734.
    1. Smith B, Peterson K, Fu R, McDonagh M, Thakurta S. Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University. 2011. [ ]
    1. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;16:955–962. doi: 10.1136/annrheumdis-2011-201249.
    1. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;16:706–715. doi: 10.1093/rheumatology/kep432.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere